Trillsch, F., Schochter, F., Park-Simon, T., Reuß, A., Fehm, T., Wimberger, P., Bronger, H., Schmalfeldt, B., Sehouli, J., Marmé, F., Heitz, F., Mahner, S., Fredrich, M., Barth, S., Stec, J., Method, M., & Harter, P. (n.d.). 2022-RA-835-ESGO AGO-OVAR 2.34/MIROVA: A randomized phase II trial of Mirvetuximab soravtansine (IMGN853), in folate receptor alpha (FRα) high recurrent ovarian cancer eligible for platinum-based chemotherapy. International journal of gynecological cancer, 32, A268. http://access.bl.uk/ark:/81055/vdc_100168339599.0x00002f